Because TLR5 deficiency appears to protect against colonization with specific BVAB but does not prevent the appearance of clinically or microbiologically defined BV, it is unlikely that treatment with TLR5 antagonists would be an effective preventive measure against BV. This evidence concerns the gene TLR5 and bacterial vaginosis.